Ads
related to: immune thrombocytopenic purpura protocol- About Chronic ITP
Learn More About What It Is
& How It Is Treated.
- View Prescribing Info
Click To Find Full Prescribing
Info For This Medication.
- Connect With Coordinators
Click To Download Our Forms
Or Get Assistance.
- Join For Exclusive Tips
Sign Up For Our Community Tips
Delivered To Your Doorstep & Inbox
- About Chronic ITP
Search results
Results From The WOW.Com Content Network
Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune thrombocytopenia, is an autoimmune primary disorder of hemostasis characterized by a low platelet count in the absence of other causes.
In well designed, 24-week, Phase III trials, romiplostim was significantly more effective than placebo in achieving the primary endpoint of a protocol-defined durable platelet response in nonsplenectomized or splenectomized adults with chronic immune thrombocytopenic purpura. [3]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Anti-platelet autoantibodies in a pregnant woman with immune thrombocytopenic purpura will attack the patient's own platelets and will also cross the placenta and react against fetal platelets. Therefore, ITP is a significant cause of fetal and neonatal immune thrombocytopenia.
Rh o (D) immune globulin (RhIG) is a medication used to prevent RhD isoimmunization in mothers who are RhD negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. [2] It is often given both during and following pregnancy. [2] It may also be used when RhD-negative people are given RhD-positive blood. [2]
Rozrolimupab is a recombinant antibody mixture, specifically containing 25 Rhesus D, or RhD, human antibodies, and is currently under development by Symphogen for the treatment of immune thrombocytopenic purpura (ITP) and for the prevention of hemolytic disease of the newborn (HDN). [1] [2]
Ads
related to: immune thrombocytopenic purpura protocol